PharmaShots | Incisive News in 3 Shots

Subscribe Now

Atara Biotherapeutics

Atara Biotherapeutics Reports the US FDA’s BLA Acceptance with Priority Review of Tabelecleucel to Treat Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics Reports the US FDA’s BLA Acceptance with Priority Review of Tabelecleucel to Treat Post-Transplant Lymphopro...

July 18, 2024

PharmaShots Weekly Snapshots (May 27 – May 31, 2024)

PharmaShots Weekly Snapshots (May 27 – May 31, 2024)

May 31, 2024

Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases

Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases

May 30, 2024

Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis

November 9, 2023

Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally

Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Glob...

November 6, 2023

Atara Biotherapeutics Ebvallo (tabelecleucel) Receives EC’s Approval for Epstein‑Barr Virus Positive Post‑Transplant Lymphoproliferative Disease

Atara Biotherapeutics Ebvallo (tabelecleucel) Receives EC’s Approval for Epstein‑Barr Virus Positive Post‑Transplant Lymphoprolife...

December 20, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us